![Jin Zhong Zhang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jin Zhong Zhang
Chief Executive Officer at Eluminex Biosciences (Suzhou) Ltd.
Profile
Jin Zhong Zhang is the founder, Chairman, and CEO of Eluminex Biosciences (Suzhou) Ltd., which was founded in 2020.
Jin Zhong Zhang active positions
Companies | Position | Start |
---|---|---|
Eluminex Biosciences (Suzhou) Ltd.
![]() Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | Chief Executive Officer | 01/01/2020 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Eluminex Biosciences (Suzhou) Ltd.
![]() Eluminex Biosciences (Suzhou) Ltd. BiotechnologyHealth Technology Eluminex Biosciences (Suzhou) Ltd. is a privately held biotechnology company located in Suzhou, China. Eluminex Biosciences is committed to developing innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in various markets. The Chinese company focuses on ophthalmology and recombinant human collagen technology, with a goal to become a leading healthcare company in developing irreversible loss of optical quality of the cornea due to disease or damage, diabetic macular edema, and wet age-related macular degeneration. The company was founded in 2020 by Jin Zhong Zhang, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Jin Zhong Zhang